Bei CARD14-Mutationen werden zwei sich unterschiedlich manifestierende Hauterkrankungen unterschieden, die beide der Gruppe der Psoriasis zugeordnet werden.
1. |
Kint A et. al. () Pityriasis rubra pilaris, a familial condition. |
2. |
Giardina E et. al. (2006) PSORS2 markers are not associated with psoriatic arthritis in the Italian population. |
3. |
Stuart P et. al. (2006) Analysis of RUNX1 binding site and RAPTOR polymorphisms in psoriasis: no evidence for association despite adequate power and evidence for linkage. |
4. |
Capon F et. al. (2004) Genetic analysis of PSORS2 markers in a UK dataset supports the association between RAPTOR SNPs and familial psoriasis. |
5. |
Speckman RA et. al. (2003) Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. |
7. |
Matthews D et. al. (1995) Confirmation of genetic heterogeneity in familial psoriasis. |
8. |
Nair RP et. al. () Scanning chromosome 17 for psoriasis susceptibility: lack of evidence for a distal 17q locus. |
9. |
Sehgal VN et. al. (2006) (Juvenile) Pityriasis rubra pilaris. |
10. |
Sehgal VN et. al. () Familial pityriasis rubra pilaris (adult classic-I): a report of three cases in a single family. |
11. |
Sehgal VN et. al. (2000) Pityriasis rubra pilaris (PRP): report of four cases. |
12. |
Vanderhooft SL et. al. (1995) Familial pityriasis rubra pilaris. |
13. |
None (1984) Pityriasis rubra pilaris. Etiologic considerations. |
14. |
Parish LC et. al. (1969) Pityriasis rubra pilaris in Korea. Treatment with methotrexate. |
15. |
Helms C et. al. (2003) A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. |
16. |
None (1992) Pityriasis rubra pilaris: the problem of its classification. |
17. |
Wang M et al. (2018) Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A. |
18. |
Fuchs-Telem D et. al. (2012) Familial pityriasis rubra pilaris is caused by mutations in CARD14. |
19. |
Jordan CT et al. (2012) Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. |
20. |
Jordan CT et. al. (2012) PSORS2 is due to mutations in CARD14. |
21. |
Yang CF et al. (2008) A promoter sequence variant of ZNF750 is linked with familial psoriasis. |
22. |
Hwu WL et. al. (2005) Mapping of psoriasis to 17q terminus. |
23. |
Gaide O et al. (2001) Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation. |
24. |
Bertin J et al. (2001) CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. |
25. |
Tomfohrde J et. al. (1994) Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. |
26. |
Nair RP et al. (1997) Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. |
27. |
Krber A et. al. (2013) Mutations in IL36RN in patients with generalized pustular psoriasis. |